AZD-9164, a muscarinic M3 receptor antagonist, is developed for potential use in treating chronic obstructive pulmonary disease. It is anticipated that AZD-9164 could surpass tiotropium's therapeutic index by enhancing both the extent and persistence of pulmonary function improvements, while not amplifying systemically-mediated adverse events.
Marketplace OffersShowing from 2 suppliers
Supplier
TargetMolSC
Pack Size
Estimated Lead Time
10-14 weeks
Purity
-
Inquiry
1
Supplier
TargetMolSC
Pack Size
Estimated Lead Time
10-14 weeks
Purity
-
Inquiry
1
You cannot determine which compound library is the best fit for your project? Do you need a custom solution? AnyMol is always ready to help you.